Shandong Xinhua Pharmaceutical (HKG:0719) obtained a drug registration certificate in China for its ketorolac tromethamine injection, a prescription painkiller.

The injection is approved for short-term treatment of moderate-to-severe acute pain in adults, including postoperative pain, according to a Friday Hong Kong bourse filing.